MetaTrader
  • Mercati
  • Grafici & Idee
  • Algo
  • Notizie
  • Store
  • Broker
  • Scarica
  • Calendario Economico
  • Segnali di Trading
  • Terminale Web
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Türkçe Türkçe
Keros Therapeutics, Inc. Common Stock

KROS

#2419
Keros Therapeutics, Inc. Common Stock
14.1900
-3.14%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
14.1900
14.1900
Intervallo Annuale
14.6500
22.5500
Variazione giornaliera
-3.14%
Variazione Mensile
-21.86%
Variazione di 6 mesi
-6.03%
Variazione Annuale
-6.03%
Chiusura Precedente
14.6500
Open
14.1900
Bid
Ask
Low
14.1900
High
14.1900
Volume
60
  1. Mercati
  2. Mercato Azionario Statunitense
  3. Salute
  4. KROS
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

Notizie

Investing Investing
KROS
l’altro ieri, 21:14
Keros Therapeutics nomina l’ex CFO di Lyell nel consiglio
Zacks Zacks
SRPT TAK KROS
2026.02.18
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
Zacks Zacks
BMY JNJ KROS
2026.02.03
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
Zacks Zacks
ALKS SRPT CSTL KROS
2026.01.27
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
Zacks Zacks
DYN KROS
2026.01.27
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
Zacks Zacks
SRPT PTCT KROS
2026.01.26
Is KROS' KER-065 the Next Breakthrough in DMD Space?
Zacks Zacks
BMY FOLD KROS JANX
2026.01.23
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Zacks Zacks
MNKD FOLD IONS KROS
2026.01.22
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
Zacks Zacks
MNKD FOLD MRKR KROS
2026.01.21
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Zacks Zacks
NVS MNKD FOLD KROS
2026.01.19
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
Zacks Zacks
MNKD FOLD AXSM KROS
2026.01.16
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia
Zacks Zacks
SRPT SLDB KROS
2026.01.16
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?

Mercati

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Grafici & Idee

  • Idee di Trading
  • Idee Educative
  • Grafici

MQL5 Community

  • Market
  • Segnali
  • Forum
  • Articoli
  • CodeBase

Notizie

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Broker

  • Tutti i Broker
  • Forex
  • Azioni
  • Metalli
MetaTrader 5
MQL5 Channels
Economic Calendar
Esclusione di Responsabilità e Informativa sui Rischi Termini di Utilizzo Contatti e richieste Legale
Copyright 2000-2026, MetaQuotes Ltd